Ambrosia Bio
Ambrosia Bio42
About
What does Ambrosia Bio do?
Ambrosia Bio produces rare sugars, including Allulose, in large quantities using a proprietary solution that makes them affordable and efficient. These rare sugars offer a similar taste and texture to sugar with very low to nearly no caloric value, making them ideal sugar replacements for healthier food and beverage options. Ambrosia Bio serves manufacturers looking to diversify their product offerings with healthier ingredients.
What is Ambrosia Bio's revenue?
StartupHub estimates Ambrosia Bio's annual revenue at $1.4M (range $762K to $2.1M, 64% confidence), based on comparable companies in the sector.
Where is Ambrosia Bio headquartered?
Ambrosia Bio is headquartered in San Diego, United States.
When was Ambrosia Bio founded?
Ambrosia Bio was founded in 2018.
What industry does Ambrosia Bio operate in?
Ambrosia Bio operates in Life Sciences, Biotech, FoodTech, Enzyme Technology, Rare Sugars, Ingredient Innovation.
How many employees does Ambrosia Bio have?
Ambrosia Bio has approximately 8 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Biotalent is a platform that streamlines biotech hiring by connecting qualified candidates with job opportunities and providing hiring teams with tools for efficient candidate review.
AI-powered platform accelerating biological research and drug discovery.
A healthcare and life sciences consulting firm leveraging AI and data analytics for strategic solutions.
Empowering Life Science Entrepreneurs for Innovative Healthcare Solutions.
An entrant is a company tagged Life Sciences whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.